Skip to main content
MACROGENICS INC logo

MACROGENICS INC — Investor Relations & Filings

Ticker · MGNX ISIN · US5560991094 LEI · 5493001KJQUA83L8MH79 US Manufacturing
Open in API
Filings indexed 894 across all filing types
Latest filing 2018-10-23 Director's Dealing
Country US United States of America
Listing US MGNX

About MACROGENICS INC

https://www.macrogenics.com/

MacroGenics, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative antibody-based therapeutics for the treatment of cancer. The company utilizes its proprietary antibody engineering platforms, including the DART (Dual-Affinity Re-Targeting) and TRIDENT technologies, to create novel product candidates. Its pipeline consists of investigational treatments such as monoclonal antibodies, antibody-drug conjugates (ADCs), and multi-specific antibodies. MacroGenics maintains fully-integrated capabilities, from research and discovery through to GMP (Good Manufacturing Practice) manufacturing, to advance its portfolio of potential medicines for patients with unmet medical needs.

Recent filings

Filing Released Lang Actions
FORM 4
Director's Dealing
2018-10-23 English
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated August 7, 2018, reporting the company's financial and operating results for the quarter ended June 30, 2018. It includes a press release as an exhibit announcing these results. The text explicitly states that the full text of the press release is attached as Exhibit 99.1. The document is 3402 characters long, which is relatively short and primarily serves as an announcement of the earnings results rather than containing detailed financial statements or analysis itself. According to the 'Menu vs Meal' rule, such a document is an initial announcement of quarterly financial results (key highlights only), which fits the definition of an Earnings Release (ER). Therefore, the correct classification is ER with high confidence.
2018-08-07 English
10-Q
Interim / Quarterly Report Q2 2018
2018-08-07 English
FORM 3
Director's Dealing
2018-07-04 English
8-K
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is a Form 8-K current report filed with the SEC, dated May 17, 2018, for MacroGenics, Inc. The key content is the submission of matters to a vote of security holders at the 2018 Annual Meeting of Stockholders. It details the voting results for director elections, auditor ratification, and advisory approval of executive compensation. This corresponds to official results from shareholder votes at a general meeting. The document length is 4248 characters, which is relatively short but contains detailed voting results, not just an announcement of a report. Therefore, it fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA).
2018-05-23 English
FORM 4
Director's Dealing
2018-05-21 English

Browse filings by year

19 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.